KalVista Pharmaceuticals rises after FDA nod for Ekterly

5 hours ago 1

KalVista Pharmaceuticals (NASDAQ:KALV) shares climbed on Monday after the U.S. FDA approved its plasma inhibitor, Ekterly (sebetralstat), for the treatment of hereditary angioedema in adult and pediatric patients aged 12 years and older.
KalVista said it will launch Ekterly in

Recommended For You